GBT Announces New Employment Inducement Grants
November 08 2021 - 08:00AM
GlobeNewswire Inc.
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced
that on November 1, 2021, the compensation committee of GBT’s
board of directors granted eight new employees restricted
stock units for an aggregate of 16,350 shares of the company’s
common stock. These awards were made under GBT’s Amended and
Restated 2017 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement
material to the employees entering into employment with the company
in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted
pursuant to the terms of the Plan. The Plan was adopted by GBT’s
board of directors in January 2017 and has been amended and
restated from time to time.
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company
dedicated to the discovery, development and delivery of
life-changing treatments that provide hope to underserved patient
communities. Founded in 2011, GBT is delivering on its goal to
transform the treatment and care of sickle cell disease (SCD), a
lifelong, devastating inherited blood disorder. The company has
introduced Oxbryta® (voxelotor) tablets, the first FDA-approved
treatment that directly inhibits sickle hemoglobin polymerization,
the root cause of red blood cell sickling in SCD. GBT is also
advancing its pipeline program in SCD with inclacumab, a P-selectin
inhibitor in Phase 3 development to address pain crises associated
with the disease, and GBT021601 (GBT601), the company’s
next-generation hemoglobin S polymerization inhibitor. In addition,
GBT’s drug discovery teams are working on new targets to develop
the next wave of potential treatments for SCD. To learn more,
please visit www.gbt.com and follow the company on Twitter
@GBT_news.
Contact:Steven Immergut
(media)650-410-3258simmergut@gbt.com
Courtney Roberts (investors)650-351-7881croberts@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Apr 2022 to May 2022
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From May 2021 to May 2022